A deficiency of uPAR alters endothelial angiogenic function and cell morphology
© Balsara et al; licensee BioMed Central Ltd. 2011
Received: 21 February 2011
Accepted: 2 May 2011
Published: 2 May 2011
The angiogenic potential of a cell requires dynamic reorganization of the cytoskeletal architecture that involves the interaction of urokinase-type plasminogen activator receptor (uPAR) with the extracellular matrix. This study focuses on the effect of uPAR deficiency (uPAR-/-) on angiogenic function and associated cytoskeletal organization. Utilizing murine endothelial cells, it was observed that adhesion, migration, proliferation, and capillary tube formation were altered in uPAR-/- cells compared to wild-type (WT) cells. On a vitronectin (Vn) matrix, uPAR-/- cells acquired a "fried egg" morphology characterized by circular actin organization and lack of lamellipodia formation. The up-regulation of β1 integrin, FAK(P-Tyr925), and paxillin (P-Tyr118), and decreased Rac1 activation, suggested increased focal adhesions, but delayed focal adhesion turnover in uPAR-/- cells. This accounted for the enhanced adhesion, but attenuated migration, on Vn. VEGF-enriched Matrigel implants from uPAR-/- mice demonstrated a lack of mature vessel formation compared to WT mice. Collectively, these results indicate that a uPAR deficiency leads to decreased angiogenic functions of endothelial cells.
Neovascularization, by way of angiogenesis, involves a series of tightly regulated cellular processes. As a pathological event that is required for growth and survival of tumor cells, angiogenic signals consist of growth factors released in the microenvironment by the hypoxic tumor. These growth factors activate quiescent endothelial cells (ECs), leading to disruption of cell-extracellular matrix (ECM) contacts. Subsequently, the ECs undergo concerted changes in morphology and cytoskeletal configuration . These processes enable growth factor-induced migration , followed by adhesion , proliferation, and formation of a new vascular lumen, eventually leading to development of a blood vessel . The initial disruption of the EC-ECM contact requires degradation of the ECM, which is facilitated by a variety of proteases. The urokinase-plasminogen activator receptor (uPAR) binds to urokinase-plasminogen activator (uPA) [5, 6], which in-turn localizes the activation of plasminogen (Pg) to the extracellular protease, plasmin (Pm) . Pm then catalyzes degradation of the ECM and also activates other proteases, which together facilitate EC migration. Additionally, uPAR, by lateral interactions with its transmembrane partners, e.g., integrins  and low-density lipoprotein receptor-related protein (LRP), functionally orchestrates bidirectional signaling events that affect migration, adhesion, and proliferation . The ability of uPAR to interact with cytoskeletal components, such as vinculin, Rac, and focal adhesion kinase (FAK), at sites of EC-ECM contacts, strongly implicates its role in cytoskeletal rearrangement [10–12].
uPAR can directly interact with vitronectin (Vn), and this interaction may be enhanced by uPA, thus promoting cellular events leading to angiogenesis . Several studies have shown that increased expression of uPAR, which is upregulated in different cancers [13–18], results in increased adhesion to Vn. Hence, down-regulating uPAR expression would potentially not only disrupt cell-associated uPA, but also binding to matrix proteins, thereby suppressing tumor growth and invasion. A uPAR deficiency would also affect reciprocal molecular binding of integrins to ECM proteins, modulating signaling events and cytoskeleton morphology. Thus, loss of uPAR function disrupts the integrated processes of pericellular proteolysis, cell adhesion and migration, and downstream signaling events. This is confirmed in studies that showed that attenuated uPAR expression in tumor cell lines inhibited tumor cell migration and invasiveness, and led to inactivation of ERK1/2 signaling and rearrangement of the cytoskeleton architecture [18, 19]. Further, silencing uPAR expression in CFPAC-1 and PANC-1 pancreatic ductal adenocarcinoma cell lines significantly inhibited cell proliferation and migration with an increase in apoptosis . On the other hand overexpression of uPAR in HEK293 cells increased adhesion to Vn, with marked display of protrusions and lamellipodia, compared to mock-transfected cells [20, 21]. Thus, it appears that direct interaction of uPAR with Vn leads to matrix adhesion, followed by lateral engagement with integrins, which activates downstream events such as changes in cell morphology, migration, and signal transduction .
It is apparent that changes in the physiological levels of uPAR have biological consequences in this regard. Increased expression of uPAR enhanced adhesive and migratory properties of cells accompanied by increased ERK1/2 activation , whereas diminished uPAR levels in cancer cells proved to be detrimental for tumor growth and invasiveness . However, implications of diminished uPAR expression, and its effect on the angiogenic functions of cells, are not well documented. Since uPAR plays an important role in angiogenesis, as well as coordinating various cellular responses, such as interaction with matrices, signaling, and cell morphology, a total deficiency of uPAR on these processes was comprehensively evaluated utilizing physiologically relevant primary ECs isolated from aortas of wild-type (WT) and uPAR-/- mice.
Materials and methods
Complete cell culture medium for ECs consisted of RPMI 1640 (Mediatech, Herndon, VA), 20% fetal bovine serum (Invitrogen, Carlsbad, CA), 1% antibiotic/antimycotic mixture (1000 units of penicillin, 0.1 mg of streptomycin, 0.25 μg amphotericin B) (Sigma, Saint Louis, MO), 50 μg/ml endothelial growth factor supplement (BD Biosciences, San Jose, CA), 2 mM glutamine (Mediatech), 0.1 mM amino acids (Invitrogen), and 1 μl/ml β-mercaptoethanol (Invitrogen). Primary antibodies utilized were rabbit anti-human-total FAK, rabbit anti-human-total paxillin, rabbit anti-human-phospho-FAK, rabbit anti-human RhoA, rabbit anti-human Rac1/2/3 (L129), and rabbit anti-human STAT1 were from Cell Signaling Technology (Danvers, MA). Armenian hamster anti-mouse integrin β1 monoclonal antibody, goat anti-human integrin β3, and mouse anti-porcine tubulin monoclonal antibody were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-human paxillin(P-Tyr118) polyclonal antibody conjugated to Alexa Fluor 488 was from Invitrogen. For actin visualization, phalloidin conjugated to either Alexa Fluor 488 or 594 (Invitrogen) was utilized. Where required the secondary antibodies were HRP-conjugated goat anti-rabbit IgG (Cell Signaling Technology), goat anti-mouse IgM, and goat anti-armenian hamster (Santa Cruz Biotechnology). Mouse anti-human uPA and mouse anti-human vinculin antibodies were from Abcam (Cambridge, MA) and rabbit anti-rat PAI-1 from American Diagnostica (Stamford, CT). Vitronectin was from Sigma and fibronectin and rat-tail type I collagen was from BD Biosciences. Rabbit anti-human microtubulin polyclonal antibody was kindly provided by Dr. Holly Goodson (University of Notre Dame, IN, USA).
Mice with a homozygous deficiency of urokinase-type plasminogen activator receptor (uPAR-/-) have previously been described . The uPAR-/- mice utilized in this study lacked the second and fifth exon of the uPAR gene resulting in complete inactivation of the gene product. Wild type mice (C57BL/6J) were obtained from the Jackson Laboratory (Bar Harbor, ME) and were used as controls. Male mice between 8 and 12 wks of age were utilized for this study. Mice were anesthetized intraperitoneally with a rodent mixture (0.015 mg of xylazine, 0.075 mg of ketamine, and 0.0025 mg of aceprozamine/g body weight). Experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Notre Dame.
Isolation of EC
Aortic ECs were isolated as previously described . The aortas were cut into 10 pieces and then opened longitudinally. Each segment was placed lumen side down on a collagen gel and incubated for 36 hr. Fresh media was added and cells were allowed to become confluent (7-10 days). Automated EC purification was based on selecting a subset of cells that are positive for CD105 and/or CD106 expression utilizing a RoboSep (Stem Cell Research, Vancouver, Canada). All cell culture experiments were performed at 37°C in a humidified 6.5% CO2 incubator.
Twenty four-well plates were coated with Vn (1.5 μg/ml) or Fn (10 μg/ml) at 4°C overnight. Plates coated with collagen (1 mg/ml) were incubated for 1 hr at RT. The wells were aspirated and the plates were treated with 1% BSA for 1 hr at 37°C to prevent non-specific binding. Wells coated with 40 μg/ml of BSA served as controls for the adhesion assay. ECs were placed in serum-free medium for 1 hr to induce quiescence. EC density was adjusted to 5 × 104 cells/ml in RPMI/0.2% BSA, and 1 ml was added to each well. After the designated incubation time, the cells were placed on a Jitterbug™ model 130000 (Boekel Scientific, Feasterville, PA) for 2 minutes and then washed with PBS to remove non-adherent cells. The adherent cells were fixed with cytofix, stained with Hematoxylin (Vector Laboratories), viewed with a Nikon Eclipse TE200 microscope, and imaged using the SPOT camera and the SPOT advanced version 4.0.9 software (Diagnostic Instruments, Inc.). Cell counts were determined in triplicate using a 40× objective (three fields/well).
Migration assays were performed on 6-well Vn- (1.5 ug/ml) or collagen- (1 mg/ml) coated plates. 6 × 105 quiescent cells in RPMI were added to each well and allowed to adhere overnight. The next day, a scratch was induced with a 200 μl tip, the cells washed with PBS and then incubated in RPMI containing 10 ng/ml of VEGF as a chemoattractant. Images were captured immediately after scratch induction and 24 hr after scratch induction with a Nikon Eclipse TE200 microscope utilizing a 10× objective, the SPOT camera, and SPOT advanced version 4.0.9 software. The number of cells that had migrated to the scratched area was counted. For uPA/PAI-1 colocalization staining, WT and uPAR-/- ECs were seeded on Vn-coated 2-well multi-chambered slides (Grace Biolabs, Bend, OR) and allowed to reach confluency. A scratch was then induced, and migration allowed to occur for 24 hr. The cells were fixed with 4% paraformaldehyde and stained for PAI-1 and uPA (as described for immunofluorescence).
Cells were resuspended at 1 × 105 cells/ml in complete medium. An aliquot of 1 ml was added to Vn-coated or collagen-coated 6-well plates. The cells were then incubated for 24 hr. The medium was then removed, fresh complete medium without EC growth factor supplement was added, and the plates incubated at 37°C. Total cell counts were performed at 24 and 48 hr. For this, the medium was removed, and the wells were rinsed with PBS. Adherent cells were detached either with collagenase (Invitrogen) or trypsin-EDTA, stained with trypan blue (Sigma), and counted using a hemocytometer.
WT and uPAR-/- ECs that were allowed to adhere on Vn for 4 hr were detached by trypsin-EDTA for 5 min and then lysed in cell lysis buffer (Cell Signaling Technology) for 10 min on ice. The cell lysates were centrifuged and total protein concentration of the supernatant was determined by the BCA assay (Pierce, Rockford, IL). Supernatants were fractionated on 10% SDS-PAGE gels, blotted on polyvinylidene difluoride membranes (Osmonics Inc.), and immunoassayed according to the manufacturer's protocol. Densitometric analyses of Western autoradiograms were performed using the Scion program downloaded from NIH (available on the World Wide Web at http://www.scioncorp.com).
For detection of integrins β1, β3, and FAK(P-Tyr925), immunoprecipitation of 100 μg of WT and uPAR-/- cell lysates from ECs adherent on Vn for 4 hr was performed using an antigen specific antibody and incubated overnight at 4°C. Lysates were then gently rocked for 3 hr with protein A beads (Pierce) at 4°C. The mixture was centrifuged and washed 5× in lysis buffer, suspended in SDS-PAGE loading buffer, and resolved in a 10% polyacrylamide gel. Western blots were then performed.
WT and uPAR-/- cells plated on Vn or collagen-coated multi-chambered wells (Grace Biolabs) were fixed with either 4% paraformaldehyde for 10 min. or ice-cold methanol for 5 min. Cells not fixed in methanol were permeabilized with 0.1% Triton X-100, and blocked with 10% normal serum (Jackson Immunoresearch, West Grove, PA) followed by treatment with Image-iT FX signal enhancer (Invitrogen). Cells were incubated with primary antibody, washed, and then incubated with the appropriate Alexa Fluor secondary antibody (488 or 594) (Molecular Probes). Cells stained for actin or paxillin(P-Tyr118) were permeabilized with 0.1% Triton X-100/PBS at RT for 5 min, washed 3×, and incubated with Image-iT FX for 30 min. The conjugated primary antibody diluted (1:500 for phalloidin, 1:50 for phospho-pax) in 1% BSA/PBS was then added and incubated overnight at 4°; C. After labeling, the slides were rinsed and cover slipped. Coverslips were mounted with ProLong Gold antifade reagent containing DAPI (Invitrogen). Images were captured using a Nikon Eclipse TE2000-U with the BD CARV spinning disk confocal unit and images were acquired using Metamorph 7.0 software.
Rac activity assay
Rac1 activity was measured utilizing the Rac1 activation assay kit according to the manufacturer's protocol (Thermo Scientific, Rockford, IL). WT and uPAR-/- ECs adherent on Vn for 4 hr were harvested in lysis/binding/wash buffer containing 1× protease inhibitor cocktail (Thermo Scientific). Briefly, one Immobilized Glutathione SwellGell Disc was placed in a spin tube for each genotype and to that was added 20 μg of GST-human Pak1-PBD. Immediately 800 μg of cell lysates was added, the spin tube vortexed, and then incubated at 4°C with gentle rocking for 1 hr. The resin was washed 3× with the lysis/binding/wash buffer and the Rac activation pull-down reaction was retrieved by adding 50 μl of 2× SDS Sample buffer containing 1 part β-mercaptoethanol and centrifuging at 7,200 × g for 2 min. The samples were fractionated by SDS-PAGE using a 12% gel and subjected to immunoblot analysis utilizing anti-Rac 1 mouse monoclonal antibody. The secondary antibody was goat anti-mouse HRP conjugated IgG and detection was by chemiluminescent. The presence of active Rac was determined by the appearance of the 22 kDa Rac-GTP band.
An in vivo angiogenesis assay utilizing Matrigel Basement Membrane Matrix (BD Biosciences) was performed. Matrigel solution was supplemented with VEGF (10 ng/ml) and 0.4 ml was administered to WT and uPAR-/- mice (3 mice/genotype) by dorsal subcutaneous injection. All mice utilized in this experiment were 8-10 wk old males. The implants were removed at day 14 and fixed in PLP (Paraformaldehyde/Lysine/Periodate). The excised plugs were stained for smooth muscle α-actin by first permeabilizing with 0.05% Triton X-100, followed by blocking with normal goat serum for 30 min with agitation. The gels were incubated with a mouse monoclonal antibody against human smooth muscle α-actin (Sigma) at 4°; C/overnight, washed, stained with Alexa Fluor 488 (Invitrogen) and then visualized utilizing an Olympus FV 1000 Laser Scanning Confocal microscope with ASW software (NDIIF, University of Notre Dame, USA).
In vitro sprout formation assay
The ability of WT and uPAR-/- ECs to undergo tubulogenesis, in vitro, was determined as previously described . Microcarrier cytodex (Sigma) beads were mixed with 5 × 106 cells and seeded in a fibrinogen (ERL, South Bend, IN) gel in a 2-well multi-chambered slide. Polymerization of fibrin was initiated by adding 0.48 U/ml thrombin (ERL) for 5 min at RT. To each well 1 ml of complete RPMI was added and incubated for 1 h at 37°; C, after which the medium was aspirated and 1 ml of complete RPMI in the presence or absence of 10 ng/ml VEGF was added. The mixture was allowed to incubate for either 24 or 96 hr at 37°; C/6.5% CO2, after which the gel was fixed with 1% paraformaldehdye/PBS for 3 h at 4°; C. The cells were permeabilized with 0.3% Triton X-100 for 5 min at room temperature and then treated with Image-iT Fx Signal Enhancer (Invitrogen) for 30 min. The cells were washed with PBS 3× and blocked with a serum-free protein block (DAKO, Denmark) for 5 min. The cells were then incubated overnight at 4°; C with phalloidin Alexa Fluor 594 (Invitrogen) to stain for actin. The next day the cells were washed 3× with PBS and the gels were mounted with DAPI containing ProLong Antifade reagent (Invitrogen).
Quantification of vessels in vitro
High resolution images of the beads (up to 10 beads/well of each genotype/treatment) were acquired using a Nikon TE 2000 S fluorescence microscope. The objective used was 100× (Nikon). The images were taken as a z series stack, which allowed the inclusion of all sprouts. The software interface NIS Nikon Elements was used to capture the images as well as to quantify the number of cells adherent per bead (performed by counting the nuclei on a bead), sprouts per bead, and the sprout length. After a 96 h incubation, images were acquired using a 20× ELWD objective. All experiments were repeated three times.
All experiments were performed at least three times. The data are represented as the mean ± SEM and p values of ≤ 0.05 obtained using Student's t test were considered to be statistically significant.
A total uPAR deficiency perturbs adhesion, migration, and proliferation of ECs
Altered morphology of uPAR-/- ECs is Vn-dependent
Microtubules functionally interact with the actin cytoskeleton and together they organize the cytoskeleton architecture, thus facilitating cell migration [32–34]. To determine whether lack of uPAR has an influence on microtubule configuration, WT and uPAR-/- ECs adherent to Vn and collagen were stained with an antibody specific for polymerized α-tubulin (kindly provided by Dr. Holly Goodson). When WT and uPAR-/- ECs were plated on Vn, no differences in the morphology of microtubule organization were noted. Both genotypes exhibited a prominent microtubule-organizing center (MTOC) with the microtubules growing radially towards the cell periphery (Additional File 1, Figure S1A,B). However, on collagen the microtubulin organizations in uPAR-/- ECs appeared to be arranged in parallel bundles, as opposed to the radial petal-like configuration observed in WT cells (Additional File 1, Figure S1C,D). This may be a function of microtubules in uPAR-/- cells having a greater number of contact points with the cell cortex, as the petal motif in the WT cells arise from the convergence of microtubules to a few specific points on the membrane.
Effect of uPAR-deficiency on cytoskeletal-associated signaling in ECs
Paxillin is another major component of the focal adhesion complex playing a pivotal role in cell attachment and motility. This adaptor protein is phosphorylated at different sites. Phosphorylation at Tyr118 is catalyzed by FAK  and this step is important for coordinating formation of focal adhesions and associated actin network . Immunofluorescence staining was performed on WT and uPAR-/- ECs after 4 hr adhesion on Vn to determine the localization and distribution of Pax(P-Tyr118). In WT cells, Pax(P-Tyr118) was present as plaques in the lamellipodia protrusions, whereas in the uPAR-/- ECs there is complete lack of lammellipodia and the Pax(P-Tyr118) was observed as focal adhesions around the cell periphery and central region (Figure 5C,D). Localization of Pax(P-Tyr118) at focal adhesions, and actin organization, are inter-dependent processes [44, 45], and tethered to the actin filaments . Therefore, changes to the actin organization can affect the localization of paxillin. Since in uPAR-/- ECs actin organization is circular, corresponding peripheral and central circular localizations of Pax(P-Tyr118) were observed in these cells (Figure 5D). In adherent WT cells that showed polarized actin organization and robust lamellipodia formation, Pax(P-Tyr118)-containing focal adhesions were associated with lamellipodia protrusions.
It has been reported that modification of cytoskeletal proteins affects paxillin expression . However, changes in the actin network in uPAR-/- cells had little effect on the expression of paxillin (Figure 5E). Since vinculin is another component of focal adhesions and is associated with paxillin , adherent cells were immunostained for vinculin after 4 hr. It was observed that in both WT and uPAR-/- ECs plated on Vn, cellular localization of vinculin was more perinuclear (Additional File 2, Figure S2A,B). Cellular localization of vinculin on WT and uPAR-/- ECs plated on collagen was associated with focal adhesions (Additional File 2, Figure S2C,D). Thus, it appears that subcellular localization of vinculin is independent of actin organization or uPAR, but dependent on the type of ECM on which the cells are plated.
The Rho family of GTPases, viz., Rac1, cdc42, and RhoA, play an important role in actin cytoskeleton regulation of lamellipodia and filopodia formation, thus controlling cell adhesion, motility, and growth [48, 49]. Rac activation is dependent on the interaction of uPAR with Vn followed by protrusive activity and lamellipodia formation . To investigate whether Rac activation is affected in uPAR-/- cells adherent on Vn, conditions where cell morphology was affected, levels of activated Rac were determined on ECs after 4 hr of adhesion. As observed in Additional File 3, figure S3A, GTP-loaded Rac was diminished in uPAR-/- ECs, but was present in WT cells. Since functioning of Rac and RhoA is interconnected, and RhoA regulates formation of actin bundles and focal adhesions, the spatial arrangement of Rho was examined in WT and uPAR-/- cells on Vn and collagen. In WT cells, RhoA is located centrally throughout the cell when plated on VN and collagen (Additional File 3, Figure S3B,D). On the other hand, in the uPAR-/- ECs, RhoA appears to be present on the membrane when adhered to collagen, but is perinuclear when plated on Vn (Additional File 3, Figure S3E,C). The central localization of Rho in WT cells is consistent with its function of generating tension and stabilizing adhesions .
ECs interact with Vn via members of the integrin family of ECM receptors, which in-turn are known to mediate tyrosine phosphorylation of FAK, thus regulating cell adhesion and migration . In particular, it is known that ECs predominantly bind to Vn via the α5β1 and αVβ3 integrins , and that uPAR is known to associate with β1 and β3 integrins . Given our observation that uPAR-/- ECs demonstrate perturbations in adhesive properties, key components of the cytoskeletal components, and focal adhesions, expression levels of β1 and β3 integrins in cells adherent to Vn for 4 hr were evaluated. It was observed that β1 integrin levels were elevated in uPAR-/- ECs (Figure 5E,F), whereas expression of β3 integrins was similar to WT cells (Figure 5E). These results suggest that absence of uPAR increased expression of β1 integrin leading to higher levels of Vn cell surface receptors and elevated adhesion of uPAR-/- cells to Vn. It has been shown that STAT1 plays an important role in cell adhesion in different cell types and that STAT1-/- embryonic fibroblasts demonstrated higher levels of adhesiveness and decreased migration on fibronectin compared to WT cells [54, 55]. Therefore, STAT1 levels were evaluated in WT and uPAR-/- ECs after 4 hr of adhesion on Vn. STAT1 levels in uPAR-/- ECs were lower compared to WT cells (Figure 5E,F).
Sprout formation and capillary morphogenesis is impaired in uPAR-/- ECs
uPAR-/- mice demonstrate impaired neovascularization in vivo
It is proposed that the circular actin organization observed when uPAR-/- ECs were plated on Vn, and the associated increased levels of other proteins, such as FAK(P-Tyr925) and Paxillin, could be responsible for the uPAR-/- EC phenotypes on Vn. Mechanistically, the interaction of uPAR with Vn leads to Rac activation, which in turn affects actin organization and formation of protrusions in an uPA-independent manner in Swiss 3T3 cells . The uPAR-/- ECs adherent on Vn lacked GTP-loaded Rac. RhoA localization in these cells was mostly present at the peripheral edge when cells adhered to collagen and perinuclear when adhered to Vn. This suggests that in order to have normal associated cytoskeletal structures and actin organization when bound to Vn the cells must express uPAR. However, the perinuclear localization of vinculin in WT and uPAR-/- ECs, which is another important component of the focal adhesion complex and is known to complex with FAK and paxillin, was dependent on Vn. Vinculin at focal adhesions was observed only when WT and uPAR-/- ECs were plated on collagen and hence its localization is uPAR-independent.
uPAR-/- ECs expressed decreased levels of STAT1 relative to WT cells. It has been reported that absence of STAT1 signaling is accompanied by increased cell adhesion on fibronectin, but poor migration , an observation that was similar to that observed in uPAR-/- ECs. Since cell adhesion and cytoskeleton morphology is intrinsically linked with migration, the decreased migration of uPAR-/- ECs on Vn is probably associated with the perturbed cytoskeletal organization and engagement of focal adhesion proteins of these cells to the matrix. Gondi et al., (2004)  have shown that RNAi-mediated down regulation of uPAR expression in SNB19 human glioblastoma cells inhibited tumor cell migration, proliferation, and invasion, but had no effect on phosphorylation of ERK1/2 and FAK. Our observations regarding P-ERK1/2 are consistent with those observed in the uPAR down-regulated SNB19 cells, but in uPAR-/- ECs FAK phosphorylation was increased. This could be due to differences in cell types such as the ECs utilized in this study. Similarly, knockdown of uPAR expression in PC3 prostrate cancer cell lines also diminished cell proliferation and inhibited Matrigel invasion of PC3 cells without affecting ERK1/2 activation .
uPAR-/- ECs also exhibited diminished capacity to undergo tubulogenesis both in vitro and in vivo. The inability of the uPAR-/- ECs to form lumen-like structures in a fibrin matrix could not be related to differences in VEGF receptor signaling between WT and uPAR-/- ECs, as the VEGF receptor-1 (Flt-1) levels and its phosphorylated form were similar in the two genotypes (data not shown). Previous studies have demonstrated that these ECs do not express VEGFR-2 . It was demonstrated in systemic sclerosis microvascular ECs (SSc MVECs) that full length uPAR is required for cdc42- and Rac-mediated cytoskeletal organization. SSc MVECs express a truncated form of uPAR that lacks the D1 domain and are incapable of forming tubular-like structures. Instead, elongated cells with very little evidence of capillary-like structures were observed . Similarly, Matrigel implants excised from uPAR-/- mice and stained for α-smooth muscle actin revealed a lack of robustly formed blood vessels. For several years it was thought that the uPAR-/- mice do not have physiological abnormalities as they appeared normal and were fertile. However, several recent investigations have documented that uPAR-/- mice are deficient in several physiological functions. Bone homeostasis in uPAR-/- mice is affected due to increased bone mass, increased osteogenic potential of osteoblasts, decreased osteoclast formation, and altered cytoskeleton organization in matured osteoclasts characterized by actin rings and podosomes clusters when cultured on Vn . Wei et al., (2008)  demonstrated that a concerted signaling pathway involving uPAR/αvβ3/Vn is required for development of podocyte foot process effacement and proteinuria, thus implicating the involvement of uPAR in remodeling of the kidney barrier function. Additionally, uPAR is involved in the recruitment and infiltration of macrophages into the lungs and inflamed peritoneal cavity of mice challenged with Streptococcus pneumoniae [74, 75]. Interestingly, although uPAR-/- mice survive through adulthood they exhibit increased anxiety behavior and are susceptible to spontaneous seizure activity that are thought to be due to decreased levels of GABA-immunoreactive interneurons in the brain cortex thus causing changes in circuit organization and behavior . Thus the uPAR protein is a very versatile molecule and binding to ECM (mainly Vn) can modulate several physiological processes in a proteolytic-independent manner.
cystic fibrosis pancreatic adenocarcinoma cell
cell division cycle 42
extracellular signal-regulated kinase
focal adhesion kinase
fms-like tyrosine kinase 1
human embryonic kidney cell line 293
low-density lipoprotein receptor-related protein
plasminogen activator inhibitor-1
human pancreatic carcinoma epithelial-like cell line-1
- Rac and Rho:
Ras-related small GTPase
- SSc MVEC:
systemic sclerosis microvascular endothelial cell
signal transducer and activator of transcription 1
urokinase type plasminogen activator
urokinase-type plasminogen activator receptor
vascular endothelial growth factor
vascular endothelial growth factor receptor 2
We are thankful to Allison Ditmars for her assistance in culturing the primary ECs and Dr. Holly Goodson for insightful discussions. Our thanks to Mayra Sandoval-Cooper for her technical assistance in immunocytochemistry and imaging. This work was supported by grants HLO13423 (FJC) and HLO63682 (VAP) from the National Institutes of Health (NHLBI).
- Ingber DE: Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res. 2002, 15: 877-887.View Article
- Rabbani SA, Mazar AP: The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am. 2001, 10: 393-415.PubMed
- Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002, 8: 918-921. 10.1038/nm0902-918.View ArticlePubMed
- Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000, 6: 389-395. 10.1038/74651.View ArticlePubMed
- Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA. 1985, 82: 4939-4943. 10.1073/pnas.82.15.4939.PubMed CentralView ArticlePubMed
- Vassalli JD, Baccino D, Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985, 100: 86-92. 10.1083/jcb.100.1.86.View ArticlePubMed
- Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A: Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989, 108: 1987-1995. 10.1083/jcb.108.5.1987.View ArticlePubMed
- Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994, 1269: 32380-32388.
- Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002, 3: 932-943. 10.1038/nrm977.PubMed
- Kjøller L, Hall A: Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol. 2001, 152: 1145-1157. 10.1083/jcb.152.6.1145.PubMed CentralView ArticlePubMed
- Hedman K, Nielsen LS, Danø K, Vaheri A: Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol. 1988, 106: 87-95. 10.1083/jcb.106.1.87.View ArticlePubMed
- Myöhänen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A: Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem. 1993, 41: 1291-1301. 10.1177/41.9.8394852.View ArticlePubMed
- Pyke C, Graem N, Ralfkiaer E, Rønne E, Høyer-Hansen G, Brünner N, Danø K: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 1993, 53: 1911-1915.PubMed
- Pyke C, Ralfkiaer E, Rønne E, Høyer-Hansen G, Kirkeby L, Danø K: Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology. 1994, 24: 131-138. 10.1111/j.1365-2559.1994.tb01291.x.View ArticlePubMed
- Rømer J, Pyke C, Lund LR, Ralfkiaer E, Danø K: Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J Invest Dermatol. 2001, 116: 353-358. 10.1046/j.1523-1747.2001.01241.x.View ArticlePubMed
- Nielsen BS, Rank F, Illemann M, Lund LR, Danø K: Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer. 2007, 120: 2086-2095. 10.1002/ijc.22340.View ArticlePubMed
- Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem. 2005, 280: 36529-36540. 10.1074/jbc.M503111200.View ArticlePubMed
- Gondi CS, Kandhukuri N, Kondraganti S, Gujrati M, Olivero WC, Dinh DH, Rao JS: Down-regulation of uPAR and cathepsin B retards cofilin dephosphorylation. Int J Oncol. 2006, 28: 633-639.PubMed CentralPubMed
- Xue A, Xue M, Jackson C, Smith RC: Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling. Int J Biochem Cell Biol. 2009, 41: 1731-1738. 10.1016/j.biocel.2009.03.004.View ArticlePubMed
- Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N: uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol. 2007, 177: 927-939. 10.1083/jcb.200612058.PubMed CentralView ArticlePubMed
- Hillig T, Engelholm LH, Ingvarsen S, Madsen DH, Gårdsvoll H, Larsen JK, Ploug M, Danø K, Kjøller L, Behrendt NA: Composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J Biol Chem. 2008, 283: 15217-15223. 10.1074/jbc.C700214200.PubMed CentralView ArticlePubMed
- Gondi CS, Rao JS: Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol. 2009, 487: 267-281.PubMed CentralPubMed
- Dewerchin M, Nuffelen AV, Wallays G, Bouche A, Moons L, Carmeliet P, Mulligan RC, Collen D: Generation and characterization of urokinase receptor-deficient mice. J Clin Invest. 1996, 97: 870-878. 10.1172/JCI118489.PubMed CentralView ArticlePubMed
- Ploplis VA, Balsara R, Sandoval-Cooper MJ, Yin ZJ, Batten J, Modi N, Gadoua D, Donahue D, Martin JA, Castellino FJ: Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice. J Biol Chem. 2004, 279: 6143-6151.View ArticlePubMed
- Rajashekhar G, Willuweit A, Patterson CE, Sun P, Hilbig A, Breier G, Helisch A, Clauss M: Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. J Vasc Res. 2006, 43: 193-204. 10.1159/000090949.View ArticlePubMed
- Folkman J, Moscona A: Role of cell shape in growth control. Nature (Lond.). 1978, 273: 345-349. 10.1038/273345a0.View Article
- Waltz DA, Chapman HA: Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 1994, 269: 14746-14750.PubMed
- Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA: Regulation of integrin function by the urokinase receptor. Science. 1996, 273: 1551-1555. 10.1126/science.273.5281.1551.View ArticlePubMed
- Yebra M, Parry GC, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA: Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem. 1996, 271: 29393-29399. 10.1074/jbc.271.46.29393.View ArticlePubMed
- Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F: The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 2002, 99: 1359-1364. 10.1073/pnas.022652999.PubMed CentralView ArticlePubMed
- Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990, 9: 1079-85.PubMed CentralPubMed
- Liao G, Nagasaki T, Gundersen GG: Low concentrations of nocodazole interfere with fibroblast locomotion without significantly affecting microtubule level: implications for the role of dynamic microtubules in cell locomotion. J Cell Sci. 1995, 108: 3473-3483.PubMed
- Watanabe T, Noritake J, Kaibuchi K: Regulation of microtubules in cell migration. Trends Cell Biol. 2005, 15: 76-83. 10.1016/j.tcb.2004.12.006.View ArticlePubMed
- Waterman-Storer CM, Salmon E: Positive feedback interactions between microtubule and actin dynamics during cell motility. Curr Opin Cell Biol. 1999, 11: 61-67. 10.1016/S0955-0674(99)80008-8.View ArticlePubMed
- Burridge K, Fath K, Kelly T, Nuckolls G, Turner C: Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol. 1988, 4: 487-525. 10.1146/annurev.cb.04.110188.002415.View ArticlePubMed
- Burridge K, Turner CE, Romer LH: Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol. 1992, 119: 893-903. 10.1083/jcb.119.4.893.View ArticlePubMed
- Calalb MB, Polte TR, Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 1995, 15: 954-63.PubMed CentralView ArticlePubMed
- Calalb MB, Zhang X, Polte TR, Hanks SK: Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem Biophys Res Commun. 1996, 228: 662-8. 10.1006/bbrc.1996.1714.View ArticlePubMed
- Schlaepfer DD, Hanks SK, Hunter T, van der Geer P: Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 1994, 372: 786-791.View ArticlePubMed
- Schlaepfer DD, Hunter T: Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol. 16: 5623-33. Erratum in: Mol. Cell. Biol. 1996, 16:7182-184
- Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO: SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol. 2004, 24: 8113-8133. 10.1128/MCB.24.18.8113-8133.2004.PubMed CentralView ArticlePubMed
- Katz BZ, Romer L, Miyamoto S, Volberg T, Matsumoto K, Cukierman E, Geiger B, Yamada KM: Targeting membrane-localized focal adhesion kinase to focal adhesions: roles of tyrosine phosphorylation and SRC family kinases. J Biol Chem. 2003, 278: 29115-29120. 10.1074/jbc.M212396200.View ArticlePubMed
- Bellis SL, Miller JT, Turner CE: Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. J Biol Chem. 1995, 270: 17437-17441. 10.1074/jbc.270.29.17437.View ArticlePubMed
- Richardson A, Malik RK, Hildebrand JD, Parsons JT: Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phosphorylation. Mol Cell Biol. 1997, 17: 6906-6914.PubMed CentralView ArticlePubMed
- Hu YL, Haga JH, Miao H, Wang Y, Li YS, Chien S: Roles of microfilaments and microtubules in paxillin dynamics. Biochem Biophys Res Commun. 2006, 348: 1463-1471. 10.1016/j.bbrc.2006.08.022.View ArticlePubMed
- Nikolopoulos SN, Turner CE: Actopaxin, a new focal adhesion protein that binds paxillin LD motifs and actin and regulates cell adhesion. J Cell Biol. 2000, 151: 1435-1448. 10.1083/jcb.151.7.1435.PubMed CentralView ArticlePubMed
- Gilmore AP, Burridge K: Regulation of vinculin binding to talin and actin by phosphatidyl-inositol-4-5-bisphosphate. Nature. 1996, 381: 531-535. 10.1038/381531a0.View ArticlePubMed
- Van Aelst L, D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev. 1997, 11: 2295-322. 10.1101/gad.11.18.2295.View ArticlePubMed
- Merajver SD, Usmani SZ: Multifaceted role of Rho proteins in angiogenesis. J Mammary Gland Biol Neoplasia. 2005, 10: 291-298. 10.1007/s10911-006-9002-8.View ArticlePubMed
- Rottner K, Hall A, Small JV: Interplay between Rac and Rho in the control of substrate contact dynamics. Current Biol. 1999, 9: 640-648. 10.1016/S0960-9822(99)80286-3.View Article
- Burridge K, Fath K, Kelly T, Nuckolls G, Turner C: Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol. 1988, 4: 487-525. 10.1146/annurev.cb.04.110188.002415.View ArticlePubMed
- Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992, 69: 11-25. 10.1016/0092-8674(92)90115-S.View ArticlePubMed
- Xue W, Mizukami I, Todd RF, Petty HR: Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997, 57: 1682-1689.PubMed
- Coccia EM, Del Russo N, Stellacci E, Testa U, Marziali G, Battistini A: STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. Int Immunol. 1999, 11: 1075-1083. 10.1093/intimm/11.7.1075.View ArticlePubMed
- Bandyopadhyay SK, de la Motte CA, Kessler SP, Hascall VC, Hill DR, Strong SA: Hyaluronan-Mediated leukocyte adhesion and dextran sulfate sodium-induced colitis Are attenuated in the absence of Signal transducer and activator of transcription 1. Am J Path. 2008, 173: 1361-1368. 10.2353/ajpath.2008.080444.PubMed CentralView ArticlePubMed
- Chalupowicz DG, Chowdhury ZA, Bach TL, Barsigian C, Martinez J: Fibrin II induces endothelial cell capillary tube formation. J Cell Biol. 1995, 130: 207-215. 10.1083/jcb.130.1.207.View ArticlePubMed
- Dejana E, Colella S, Languino LR, Balconi G, Corbascio GC, Marchisio PC: Fibrinogen induces adhesion, spreading, and microfilament organization of human endothelial cells in vitro. J Cell Biol. 1987, 104: 1403-1411. 10.1083/jcb.104.5.1403.View ArticlePubMed
- Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E: Participation of the urokinase receptor in neutrophil efferocytosis. Blood. 2009, 114: 860-870. 10.1182/blood-2008-12-193524.PubMed CentralView ArticlePubMed
- Mohri H, Ohkubo T: How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol. 1991, 96: 605-609.PubMed
- Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Medicine. 1996, 2: 529-533. 10.1038/nm0596-529.View ArticlePubMed
- Tomasini-Johansson BR, Milbrink J, Pejler G: Vitronectin expression in rheumatoid arthritic synovia--inhibition of plasmin generation by vitronectin produced in vitro. Br J Rheumatol. 1998, 37: 620-629. 10.1093/rheumatology/37.6.620.View ArticlePubMed
- McKeown-Longo PJ, Panetti TS: Structure and function of vitronectin. Trends Glycosci Glycotechnol. 1996, 8: 327-340.View Article
- Aguirre Ghiso JA, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999, 147: 89-104. 10.1083/jcb.147.1.89.View ArticlePubMed
- Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski L: A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J Biol Chem. 2006, 281: 14852-14863. 10.1074/jbc.M512311200.View ArticlePubMed
- Dass CR, Anne P, Nadesapillai W, Robin D, Howard ML, Fisher JL, Zhou H, Choong PF: Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clinical and Experimental Metastasis. 2005, 22: 643-652. 10.1007/s10585-006-9004-3.View ArticlePubMed
- Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA: A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999, 144: 1285-1294. 10.1083/jcb.144.6.1285.PubMed CentralView ArticlePubMed
- Hehlgans S, Haase M, Cordes N: Signalling via integrins: Implications for cell survival and anticancer strategies. Biochimica et Biophysica Acta. 2007, 1775: 163-180.PubMed
- Zouq NK, Keeble JA, Lindsay J, Valentijn AJ, Zhang L, Mills D, Turner CE, Streuli CH, Gilmore AP: FAK engages multiple pathways to maintain survival of fibroblasts and epithelia-differential roles for paxillin and p130Cas. J Cell Sci. 2009, 122: 357-367. 10.1242/jcs.030478.PubMed CentralView ArticlePubMed
- Xie B, Zhao J, Kitagawa M, Durbin J, Madri JA, Guan JL, Fu XY: Focal adhesion kinase activates Stat1 in integrin-mediated cell migration and adhesion. J Biol Chem. 2001, 276: 19512-19523. 10.1074/jbc.M009063200.View ArticlePubMed
- Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS: RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene. 2004, 23: :8486-8496. 10.1038/sj.onc.1207879.View Article
- Margheri F, Manetti M, Serratì S, Nosi D, Pucci M, Matucci-Cerinic M, Kahaleh B, Bazzichi L, Fibbi G, Ibba-Manneschi L, Del Rosso M: Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006, 54: 3926-3938. 10.1002/art.22263.View ArticlePubMed
- Furlan F, Galbiati C, Jorgensen NR, Jensen JE, Mrak E, Rubinacci A, Talotta F, Verde P, Blasi F: Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res. 2007, 22: 1387-96. 10.1359/jbmr.070516.View ArticlePubMed
- Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J: Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008, 14: 55-63. 10.1038/nm1696.View ArticlePubMed
- Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol. 2002, 168: 3507-3511.View ArticlePubMed
- May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT: Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998, 188: 1029-37. 10.1084/jem.188.6.1029.PubMed CentralView ArticlePubMed
- Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P: Genetic Disruption of Cortical Interneuron Development Causes Region- and GABA Cell Type Specific Deficits, Epilepsy, and Behavioral Dysfunction. The J Neuroscience. 2003, 23: 622-631.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.